Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271


Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.

Chen JG, Cai J, Wu HL, Xu H, Zhang YX, Chen C, Wang Q, Xu J, Yuan XL.

World J Gastroenterol. 2012 Jun 7;18(21):2682-8. doi: 10.3748/wjg.v18.i21.2682.


Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2009;9(10):1-40. Epub 2009 Sep 1.


Transferrin dipstick as a potential novel test for colon cancer screening: a comparative study with immuno fecal occult blood test.

Sheng JQ, Li SR, Wu ZT, Xia CH, Wu X, Chen J, Rao J.

Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2182-5. doi: 10.1158/1055-9965.EPI-09-0309.


Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies.

Hirai HW, Tsoi KK, Chan JY, Wong SH, Ching JY, Wong MC, Wu JC, Chan FK, Sung JJ, Ng SC.

Aliment Pharmacol Ther. 2016 Apr;43(7):755-64. doi: 10.1111/apt.13556. Epub 2016 Feb 9. Review.


KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.

Battaglia P, Baritono E, Remo A, Vendraminelli R, Conti A.

Tumori. 2014 Mar-Apr;100(2):122-7. doi: 10.1700/1491.16391.


Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.

Shastri YM, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rösch W, Mössner J, Stein JM.

Am J Gastroenterol. 2008 Jun;103(6):1496-504. doi: 10.1111/j.1572-0241.2008.01824.x. Epub 2008 May 28.


A Comparison of the Cost-Effectiveness of Fecal Occult Blood Tests with Different Test Characteristics in the Context of Annual Screening in the Medicare Population [Internet].

van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Aug 9.


A multicenter prospective study of immunochemical fecal occult blood testing for colorectal cancer detection.

Lohsiriwat V, Thavichaigarn P, Awapittaya B.

J Med Assoc Thai. 2007 Nov;90(11):2291-5.


The Relationship between the Methylated Septin-9 DNA Blood Test and Stool Occult Blood Test for Diagnosing Colorectal Cancer in Taiwanese People.

Chen CH, Yan SL, Yang TH, Chen SF, Yeh YH, Ou JJ, Lin CH, Lee YT, Chen CH.

J Clin Lab Anal. 2017 Jan;31(1). doi: 10.1002/jcla.22013. Epub 2016 Jul 8.


The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings.

Elsafi SH, Alqahtani NI, Zakary NY, Al Zahrani EM.

Clin Exp Gastroenterol. 2015 Sep 9;8:279-84. doi: 10.2147/CEG.S86419. eCollection 2015.


Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test.

Koga Y, Yamazaki N, Yamamoto Y, Yamamoto S, Saito N, Kakugawa Y, Otake Y, Matsumoto M, Matsumura Y.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1844-52. doi: 10.1158/1055-9965.EPI-13-0512. Epub 2013 Aug 15.


Comparison of fecal occult blood tests for colorectal cancer screening in an Alaska Native population with high prevalence of Helicobacter pylori infection, 2008-2012.

Redwood D, Provost E, Asay E, Roberts D, Haverkamp D, Perdue D, Bruce MG, Sacco F, Espey D.

Prev Chronic Dis. 2014 Apr 10;11:E56. doi: 10.5888/pcd11.130281.


Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan.

Ou CH, Kuo FC, Hsu WH, Lu CY, Yu FJ, Kuo CH, Wang JY, Wu MT, Shiea J, Wu DC, Hu HM.

J Dig Dis. 2013 Sep;14(9):474-83. doi: 10.1111/1751-2980.12077.


Antithrombotic drug does not affect the positive predictive value of an immunochemical fecal occult blood test.

Tsuji Y, Gunji T, Sato H, Ono A, Ito T, Ohata K, Yamamichi N, Fujishiro M, Matsuhashi N, Koike K.

Dig Endosc. 2014 May;26(3):424-9. doi: 10.1111/den.12208. Epub 2013 Dec 10.


Prevalence of colorectal diseases in immunological fecal occult blood test (I-FOBT) positive patients in a tertiary care hospital in Bangladesh.

Mollick SH, Roy PK, Bhuiyan MR, Mia AR, Alam MS, Mollick KA, Pervin S, Hassan MQ.

Mymensingh Med J. 2014 Oct;23(4):764-9.


Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis.

Zhu MM, Xu XT, Nie F, Tong JL, Xiao SD, Ran ZH.

J Dig Dis. 2010 Jun;11(3):148-60. doi: 10.1111/j.1751-2980.2010.00430.x.


The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.

Kim YC, Kim JH, Cheung DY, Kim TH, Jun EJ, Oh JW, Kim CW, Chung WC, Kim BW, Kim SS, Kim JI, Park SH, Kim JK.

Gut Liver. 2015 Sep 23;9(5):641-8. doi: 10.5009/gnl13457.


Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).

Katičić M, Antoljak N, Kujundžić M, Stamenić V, Skoko Poljak D, Kramarić D, Stimac D, Strnad Pešikan M, Samija M, Ebling Z.

World J Gastroenterol. 2012 Aug 28;18(32):4300-7. doi: 10.3748/wjg.v18.i32.4300.


Fecal cytology in conjunction with immunofecal occult blood test for colorectal cancer screening.

Sheng JQ, Li SR, Su H, Li JS, Sun ZQ, Wu ZT, Wu X, Xia CH, Rao J.

Anal Quant Cytol Histol. 2010 Jun;32(3):131-5.


Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.

Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV.

J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70. Epub 2007 Sep 25.


Supplemental Content

Support Center